异动解读 | 荣昌生物盘中大涨7.75%,泰它西普获优先审评资格

异动解读
Sep 29

今日盘中,港股荣昌生物(09995)股价大涨7.75%,引起市场广泛关注。截至发稿,该股报价109.4港元,成交额达3.57亿港元。

消息面上,荣昌生物的重磅药物泰它西普有望获得优先审评资格,这是推动股价上涨的主要原因。据悉,9月28日,CDE官网显示,泰它西普拟纳入优先审评品种,用于治疗具有进展风险的原发性免疫球蛋白A(IgA)肾病成人患者,可显著降低蛋白尿水平。这一消息极大地提振了投资者信心。

值得注意的是,荣昌生物此前已宣布泰它西普在治疗IgA肾病的国内III期临床试验中取得积极成果。研究结果显示,与安慰剂组相比,泰它西普组患者在治疗39周时24小时尿蛋白肌酐比值(UPCR)降低了55%。泰它西普是目前唯一可同时抑制B淋巴细胞刺激因子(BLyS)和增殖诱导配体(APRIL)的药物,这两种因子在IgA肾病的发病机制中扮演着关键角色。这一突破性进展不仅凸显了泰它西普的治疗潜力,也为荣昌生物在肾病领域的市场地位带来了新的机遇。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10